{"type":"rich","version":"1.0","title":"The BioPharm Brief: Survival, Scrutiny, and a Setback","description":"Today’s BioPharm Brief looks at a phase 3 survival win for Imdelltra plus Imfinzi in first-line small cell lung cancer, FDA review of Rezolute’s ersodetug, and Novartis’s del-desiran setback in myotonic dystrophy type 1.","author_name":"The BioPharm Brief","author_url":"https://audioboom.com/channels/5167274-the-biopharm-brief","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43829922/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":"<iframe width=\"100%\" height=\"95\" src=\"https://embeds.audioboom.com/posts/8950644/embed?v=202301\" style=\"background-color: transparent; display: block; padding: 0; width: 100%\" frameborder=\"0\" allowtransparency=\"allowtransparency\" scrolling=\"no\" title=\"Audioboom player\" allow=\"autoplay\" sandbox=\"allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation\"></iframe>"}